XML 48 R31.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail) |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Sep. 28, 2016 USD ($) Agreement $ / shares shares | Nov. 30, 2016 USD ($) | Sep. 30, 2016 USD ($) $ / shares | Sep. 30, 2018 USD ($) $ / shares | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Sep. 30, 2017 USD ($) $ / shares | Jun. 30, 2017 USD ($) | Mar. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Sep. 30, 2018 USD ($) $ / shares | Sep. 30, 2017 USD ($) $ / shares | Sep. 30, 2016 USD ($) $ / shares | Aug. 01, 2018 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock issued, price per share | $ / shares |  |  |  | $ 5.25 |  |  |  |  |  |  |  | $ 5.25 |  |  |
Proceeds from the issuance of common stock |  |  |  |  |  |  |  |  |  |  |  | $ 56,585,035 | $ 12,419,119 | $ 52,231,433 |
Revenues |  |  |  | $ 11,255,000 | $ 727,375 | $ 650,125 | $ 3,509,821 | $ 8,713,785 | $ 9,342,498 | $ 8,985,930 | $ 4,365,496 | $ 16,142,321 | $ 31,407,709 | $ 158,333 |
Type of Revenue [Extensible List] |  |  |  |  |  |  |  |  |  |  |  | arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember | arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember | arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember |
Amgen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock issued, price per share | $ / shares |  |  | $ 7.16 |  |  |  |  | $ 7.16 |  |  |  |  | $ 7.16 | $ 7.16 |
Collaboration and License agreements | Amgen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement date | Sep. 28, 2016 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of agreements | Agreement | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
ARO-AMG1 Agreement | Amgen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional amount of common stock shares agreed to sell upon exercise of option | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of trading days, used to calculate share price of Common Stock, surrounding option exercise date | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash received as due under collaboration agreement |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  | $ 5,000,000 |
Deferred revenue recognized into revenue |  |  |  |  |  |  |  |  |  |  |  | $ 2,500,000 | $ 2,500,000 |  |
Collaboration and License agreements | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option payments, and development, regulatory and sales milestone payments. | $ 617,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and License agreements | Amgen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash received as due under collaboration agreement | 35,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from the issuance of common stock | $ 21,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
AMG-890 (ARO-LPA) Agreement | Amgen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash received as due under collaboration agreement |  | $ 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  | $ 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue recognized into revenue |  |  |  |  |  |  |  |  |  |  |  | 2,700,000 | 27,300,000 |  |
Amgen milestone payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000
AMG 890 (ARO-LPA) and ARO-AMG1 Agreement | Amgen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000 | $ 1,500,000 | $ 0 |
Type of Revenue [Extensible List] |  |  |  |  |  |  |  |  |  |  |  | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember |
Common Stock Purchase Agreement | Amgen |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement date | Sep. 28, 2016 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued | shares | 3,002,793 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock issued, price per share | $ / shares | $ 7.16 |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Additional amount of common stock shares agreed to sell upon exercise of option. + References No definition available. + Details
Name: | arwr_AdditionalAmountOfCommonStockSharesAgreedToSellUponExerciseOfOption
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Agreement date. + References No definition available. + Details
Name: | arwr_AgreementDate
Namespace Prefix: | arwr_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash received as due under collaboration agreement. + References No definition available. + Details
Name: | arwr_CashReceivedAsDueUnderCollaborationAgreement
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment received. + References No definition available. + Details
Name: | arwr_MilestonePaymentReceived
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of agreements. + References No definition available. + Details
Name: | arwr_NumberOfAgreements
Namespace Prefix: | arwr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Option payments, and development, regulatory and sales milestone payments. + References No definition available. + Details
Name: | arwr_OptionPaymentsAndDevelopmentRegulatoryAndSalesMilestonesPayment
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Trading Period used to calculate share price of common stock surrounding option exercise date. + References No definition available. + Details
Name: | arwr_TradingPeriodUsedToCalculateSharePriceOfCommonStockSurroundingOptionExerciseDate
Namespace Prefix: | arwr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References No definition available. + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Indicates type of revenue from product and service. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 55 -Paragraph 91 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046 + Details
Name: | us-gaap_TypeOfRevenueExtensibleList
Namespace Prefix: | us-gaap_
Data Type: | srt-types:extensibleListItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=arwr_AmgenIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_AROAMG1AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arwr_AmgenIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_AMG890AROLPAAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_AMG890AROLPAAndAROAMG1AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |